SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)

Garcia-Saenz, Jose Angel; Blancas, Isabel; Echavarria, Isabel; HINOJO, CARMEN; Margeli Vila, Mireia; Moreno, Fernando; Bellet Ezquerra, Meritxell

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Garcia-Saenz, Jose Angel
dc.contributor.author	Blancas, Isabel
dc.contributor.author	Echavarria, Isabel
dc.contributor.author	HINOJO, CARMEN
dc.contributor.author	Margeli Vila, Mireia
dc.contributor.author	Moreno, Fernando
dc.contributor.author	Bellet Ezquerra, Meritxell
dc.date.accessioned	2023-09-06T11:10:28Z
dc.date.available	2023-09-06T11:10:28Z
dc.date.issued	2023-09
dc.identifier.citation	Garcia-Saenz JA, Blancas I, Echavarria I, Hinojo C, Margeli M, Moreno F, et al. SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022). Clin Transl Oncol. 2023 Sep;25:2665–78.
dc.identifier.issn	1699-3055
dc.identifier.uri	https://hdl.handle.net/11351/10245
dc.description	Advanced breast cancer; Anti-HER2 therapy; Endocrine therapy
dc.description.abstract	Advanced breast cancer represents a challenge for patients and for physicians due its dynamic genomic changes yielding to a resistance to treatments. The main goal is to improve quality of live and survival of the patients through the most appropriate subsequent therapies based on the knowledge of the natural history of the disease. In these guidelines, we summarize current evidence and available therapies for the medical management of advanced breast cancer.
dc.language.iso	eng
dc.publisher	Springer
dc.relation.ispartofseries	Clinical and Translational Oncology;25
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Mama - Càncer - Tractament
dc.subject	Mama - Càncer - Aspectes genètics
dc.subject	Resistència als medicaments
dc.subject	Qualitat de vida
dc.subject.mesh	Breast Neoplasms
dc.subject.mesh	Drug Resistance
dc.subject.mesh	Genomics
dc.subject.mesh	Quality of Life
dc.title	SEOM–GEICAM–SOLTI clinical guidelines in advanced breast cancer (2022)
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1007/s12094-023-03203-8
dc.subject.decs	neoplasias de la mama
dc.subject.decs	resistencia a medicamentos
dc.subject.decs	genómica
dc.subject.decs	calidad de vida
dc.relation.publishversion	https://doi.org/10.1007/s12094-023-03203-8
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Garcia-Saenz JA, Moreno F] Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), CIBERONC, Madrid, Spain. [Blancas I] Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria de Granada (Ibs.Granada) and Medicine Departmen, Granada University, Granada, Spain. [Echavarria I] Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañon (IiSGM), CIBERONC, Madrid, Spain. [Hinojo C] Hospital Universitario Marqués de Valdecilla, Santander, Spain. [Margeli M] Institut Català d’Oncologia (ICO)-Badalona (Hospital Germans Trias i Pujol), B-ARGO (Badalona Applied Research Group in Oncology) and CARE (Translational Program in Cancer Research), Badalona, Spain. [Bellet M] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid	37148499
dc.identifier.wos	000982749400001
dc.rights.accessrights	info:eu-repo/semantics/openAccess